A5074142514- Venous Thromboembolism Diagnosis and Management
- Atrial Fibrillation Management and Outcomes
- Heparin-Induced Thrombocytopenia and Thrombosis
- Blood Coagulation and Thrombosis Mechanisms
- Medical Practices and Rehabilitation
- Antiplatelet Therapy and Cardiovascular Diseases
- Proteoglycans and glycosaminoglycans research
- Health and Medical Studies
- Platelet Disorders and Treatments
- Physics and Engineering Research Articles
- Medical and Health Sciences Research
- Acute Myocardial Infarction Research
- Engineering and Materials Science Studies
- Biomedical and Chemical Research
- Blood properties and coagulation
- Cardiac Arrhythmias and Treatments
- Glycosylation and Glycoproteins Research
- Intramuscular injections and effects
- Peripheral Artery Disease Management
- Consumer behavior in food and health
- Hematological disorders and diagnostics
- Metabolism and Genetic Disorders
- Cerebrovascular and Carotid Artery Diseases
- Blood Pressure and Hypertension Studies
- Myeloproliferative Neoplasms: Diagnosis and Treatment
Heidelberg University
2016-2025
University Medical Centre Mannheim
2007-2024
University Hospital Heidelberg
2013-2024
Charité - Universitätsmedizin Berlin
2024
Klinikum im Friedrichshain
2005-2024
University of Mannheim
2003-2013
GTx (United States)
1996-2011
Heidelberg University
2011
Medizinische Fakultät Mannheim
2010
Leipzig University
2005
Increasing the aglycone lipophilicity of a series polysulfated oligosaccharide glycoside heparan sulfate (HS) mimetics via attachment steroid or long chain alkyl group resulted in compounds with significantly improved vitro and ex vivo antiangiogenic activity. The potently inhibited heparanase HS-binding angiogenic growth factors displayed antitumor antimetastatic activity compared earlier series. Preliminary pharmacokinetic analyses also revealed significant increases half-life following iv...
Background With the widespread use of direct oral anticoagulants (DOACs), there is an urgent need for a rapid assay to exclude clinically relevant plasma levels. Accurate and determination DOAC levels would guide medical decision-making (1) determine potential contribution spontaneous or trauma-induced hemorrhage; (2) identify appropriate candidates reversal, (3) optimize timing surgery intervention. Methods Results The Dipstick test uses disposable strip factor Xa- thrombin inhibitors in...
In a multicenter, double-blind clinical trial in 1,968 inpatients 1 daily subcutaneous administration of LMW heparin plus 2 placebo injections or 3 × 5,000 IU unfractionated (UF) was given for 10 (8-11) days. The primary end point the incidence proximal deep-vein thrombosis pulmonary embolism. Patients were assessed during study period development by compression sonography at days and embolism scintigraphy symptomatic patients. Aim to demonstrate equivalence both treatment regimens. A total...
Summary Women with a history of venous thromboembolism (VTE), thrombophilia or both may be at increased risk thrombosis during pregnancy, but the optimal management strategy is not well defined in clinical guidelines because limited trial data. A assessment and heparin prophylaxis was evaluated pregnant women VTE. In prospective (Efficacy Thromboprophylaxis as an Intervention Gravidity [EThIG]), 810 were assigned to one three strategies according pre-defined factors related VTE thrombophilic...
Recent studies suggest that low molecular weight heparin (LMW heparin) therapy in malignancy may improve cancer survival following surgical resection. We studied prospectively whether mortality during follow-up women with previously untreated breast, and pelvic is reduced those who randomly received LMW (Certoparin) compared to patients given unfractionated (UF for thrombosis prophylaxis primary surgery. In a prospective, randomized, double-blind clinical trial, 160 Certoparin 164 UF until...
Patients with stroke are at substantial risk of thromboembolic complications and therefore require antithrombotic prophylaxis. To show the noninferiority low-molecular-weight heparin certoparin to unfractionated (UFH) for prevention complications, we performed a randomized, double-blind, active-controlled multicenter trial in patients acute ischemic stroke.Overall, 545 were randomized within 24 hours onset treatment (3000 U anti-Xa OD; n=272) or UFH (5000 TID; n=273) 12 16 days. paresis leg...
A red-fluorescent perylene diimide probe allows sensitive quantification of heparin, a widely used antithrombotic drug, in plasma and serum samples with minimal interference from matrix components.
Rivaroxaban and other oral direct factor Xa inhibitors (ODiXa) are currently developed for prophylaxis treatment of thromboembolic diseases using fixed doses. Although routine monitoring is not required, assessing the intensity anticoagulation may be useful under certain clinical conditions. ODiXa prolong coagulation times several clotting assays and, thus, their concentration determined in specific chromogenic substrate assays. So far, no standardized validated assay commercially available....
A series of polysulfated penta- and tetrasaccharide glycosides containing α(1→3)/α(1→2)-linked mannose residues were synthesized as heparan sulfate (HS) mimetics evaluated for their ability to inhibit angiogenesis. The compounds bound tightly angiogenic growth factors (FGF-1, FGF-2, VEGF) strongly inhibited heparanase activity. In addition, the exhibited potent activity in cell-based ex vivo assays indicative angiogenesis, with tetrasaccharides exhibiting comparable that pentasaccharides....
Abstract Specific mass spectrometry and direct activated factor X (Xa)- thrombin inhibition assays do not allow determination of the reversal anticoagulant effects non-vitamin K oral anticoagulants (NOACs) by prothrombin complex concentrate (PCC). The objective this study was evaluation applicability a variety commercially available global coagulation in analyzing NOAC anticoagulation PCC. Plasma whole blood were spiked with apixaban or dabigatran PCC added to these samples. Prothrombin time...
Comment on: Plasma Serotonin is Elevated in Adult Patients with Sudden Sensorineural Hearing LossThromb Haemost 2020; 120(09): 1291-1299DOI: 10.1055/s-0040-1713924
Hirudin is a small protein with strong thrombin inhibition that may be antigenic. The generation and disappearance of anti-hirudin antibodies were investigated in patients heparin-induced thrombocytopenia who treated recombinant hirudin (r-hirudin) for >/=5 days.The IgA, IgE, IgG, IgM isotypes determined by ELISA before after the start r-hirudin therapy. A total 56% (13 23) developed >/=1 antibody isotype during No IgE generated. detected 30% (7 23), 52% (12 17% (4 patients, respectively....
Heparin-induced thrombocytopenia type II is a serious, immune-mediated complication of heparin therapy. Due to its low cross-reactivity with heparin-associated antibodies (10–20%), danaparoid has successfully been administered in these patients. In recent studies, r-hirudin as potent and specific thrombin inhibitor, was demonstrated be safe effective anticoagulant. We report pregnant woman systemic lupus erythematosus recurrent venous thromboembolism who suffered from heparin-induced while...